2025-09-26
Realheart Receives Patent Approval in Japan
Västerås, Sweden, September 26, 2025 – Scandinavian Real Heart AB (publ) announces today that the company has been granted patent approval by the Japan Patent Office (JPO) concerning the automatic control of Realheart® TAH. While this is the first jurisdiction to approve the patent, the company has pending applications of the same patent in Europe, the US, India, China and Australia.
Realheart is developing Realheart® TAH, the first total artificial heart that mimics the structure and function of the native human heart. The recently approved patent (JP patent no. 7731894) covers a key technology of Realheart® TAH, entailing the automated control function of the device. The feature is an important part of the product’s value proposition, designed to provide a meaningful treatment alternative for patients awaiting a heart transplant, while providing benefits that may increase the quality of life. The structural design of Realheart® TAH aims to decrease risk factors commonly associated with currently approved artificial heart treatment devices, e.g., stroke, internal bleeding, and anemia.
The patent approval confers market protection for the device in Japan until 2041.